Incidence of Haemophilus influenzae type b among children less than 5 years and resistance to antibiotics in Iraq.
DOI:
https://doi.org/10.32007/jfacmedbagdad.571315Keywords:
Meningitis, children, Haemophilus influenzae type b, Cerebrospinal Fluid, Antibiotics.Abstract
Back ground: Meningitis is an inflammation of the protective membranes covering the brain and spinal cord that known as meninges. It is the major cause of morbidity and mortality among infants and children less than the age of 5 years.
Objectives: To determine Haemophilus influenzae type b meningitis incidence in children aged less than 5 years and choice a drug for treatment
Patients and methods: During period from Febraury 2012 to first March 2013 ,250 Cerebrospinal fluid (CSF) specimens were collected from children less than 5 years ,which clinically diagnosed with meningitis ,in several hospitals of Iraq.Microbiological, biochemical, latex agglutination test and antibiotics sensitivity were used to identify and choice the antibiotic that should be used for treatment
Results: Culturing CSF specimens identified 18 confirmed cases of Haemophilus influenzae type b meningitis among 250 CSF specimens depending on biochemical and serotyping. The incidence of Haemophilus influenzae type b meningitis among infants less one years of age was 12(66.6%) compared to 6(33.3%) for older children . Incidence among males was 11(61.1%) compared to 7(38.8%) for females. Haemophilus influenzae type b meningitis is sensitive to Ampencillin , Ciprofloxacin, Cefotaxime, Cefotriaxone, Chloramphenicol, while resistant to Trimetheprim-sulfamethoxazole and Gentomycin.
Conclusions: Haemophilus influenzae type b meningitis was most common in children less than 1 years.
Downloads
Downloads
Published
Issue
Section
License
Permit others to copy and distribute the manuscript; to extract, revise, and create another derivative
works of or from the manuscript (e.g., a translation); to incorporate the manuscript into a
collective work; and to text or data mine the article, even for commercial purposes, provided that
the author(s) is/are credited; the article's modifications should not harm the author's honor or
reputation; and the article should not be altered in a way that would cause the author to lose them
reputation. The Creative Commons Attribution 4.0 International License (CC BY 4.0) has more
information.